Search clinical trials for: resectable non-small cell lung cancer

Total 157073 results

Second Affiliated Hospital, School of Medicine,...

Not yet recruiting

Application of Pablizumab Combined With Apatinib and Chemotherapy in Resectable Non-small Cell Lung Cancer： A Prospective, Single Arm, Single Center Phase II Clinical Study of Neoadjuvant Therapy

Non-small Cell Lung Cancer

China
GU Research Network, LLC

Withdrawn

A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

United States
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company; United States Department of Defense

Completed

Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)

Lung Cancer

United States
Milton S. Hershey Medical Center

Withdrawn

Cyclin B1 Peptide-Pulsed Autologous Dendritic Cell Vaccine for Resectable Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer
AVAX Technologies

Terminated

DNP-Modified Autologous Tumor Cell Vaccine for Resectable Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer - Completely Resectable

United States
Fundación GECP

Not yet recruiting

Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free. (ARIAN)

Lung Diseases | Carcinoma, Non-Small-Cell Lung | Resectable Lung Non-Small Cell Carcinoma

Spain
Zeng Jian

Recruiting

A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC

Non Small Cell Lung Cancer

China
Tyligand Bioscience (Shanghai) Limited

Recruiting

A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Malignant Neoplasm

United States
The First Affiliated Hospital of Guangzhou Medical...

Recruiting

Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma (GALAXY-02)

Carcinoma, Squamous Cell | Lung Cancer

China
Fudan University

Recruiting

Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC

Non-small Cell Lung Cancer | Neuroendocrine Carcinoma | Histology Transformation

China
Actym Therapeutics, Inc.

Not yet recruiting

A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors

Solid Tumor

Australia
Taizhou Hospital

Not yet recruiting

High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases

Lung Cancer, Nonsmall Cell
Merck Sharp & Dohme LLC

Recruiting

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Non Small Cell Lung Cancer

United States, Israel, Taiwan, Korea, Republic of, Switzerland, Hong Kong
Medical College of Wisconsin

Not yet recruiting

Radiation Prior to TKI to Delay Progression in Advanced Driver-Mutated Non-small Cell Lung Cancers (RadiaNCe Lung X)

Non Small Cell Lung Cancer

United States
Liaoning Tumor Hospital & Institute

Not yet recruiting

Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations

Non Small Cell Lung Cancer
Zhejiang University

Not yet recruiting

The Feasibility of Dynamic Liquid Biopsy Monitoring During Neoadjuvant Treatment for EGFR-mutated NSCLC

EGF-R Positive Non-Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

Neoadjuvant Therapy With Iruplinalkib for Potentially Resectable ALK Positive NSCLC: A Single Arm, Exploratory Trial

Potentially Resectable ALK Positive Non-Small Cell Lung Cancer
ETOP IBCSG Partners Foundation
AstraZeneca AG Switzerland

Not yet recruiting

A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer. (ADOPT-lung)

Non Small Cell Lung Cancer
Ruijin Hospital
Guangdong Provincial People's Hospital

Not yet recruiting

Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer With EGFR Mutation and PD-L1 Positive Expression (TOPLINE)

Carcinoma, Non-Small-Cell Lung

China
Yonsei University

Not yet recruiting

Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer (NeoLazer)

Non-small Cell Lung Cancer

Korea, Republic of
The First Hospital of Jilin University

Recruiting

Detection of Minimal Residual Disease in Resectable Stage II-IIIB Non-small Cell Lung Cancer

Lung Cancer

China
Chang Gung Memorial Hospital
National Science and Technology Council

Recruiting

Combined Relapse Prediction Model for Resectable Non-Small Cell Patients - a Prospective Clinical Feasibility Trial

Lung Cancer | Relapse/Recurrence

Taiwan
Lawson Health Research Institute

Recruiting

Model to Predict pCR and IrAEs in Early Stage Non-small Cell Lung Cancer (Pre-PLaN)

Non-small Cell Lung Cancer Stage IB (Resectable) | Non-small Cell Lung Cancer Stage II (Resectable) | Non-small Cell Lung Cancer Stage ⅢA (Resectable)

Canada
Shandong Cancer Hospital and Institute

Recruiting

Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC

Neoadjuvant Therapy | Resectable Lung Non-Small Cell Carcinoma | IMMUNOTHERAPY | Biomarkers / Blood

China
Ningbo No.2 Hospital

Not yet recruiting

Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer (PRIORITY)

Carcinoma, Non-Small-Cell Lung
H. Lee Moffitt Cancer Center and Research Institute

Recruiting

Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)

Lung Cancer | Non Small Cell Lung Cancer

United States
Incyte Corporation

Recruiting

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Solid Tumors

United States, France, Italy, Australia, Spain, Canada, Belgium
Bristol-Myers Squibb

Recruiting

An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany (NENI)

Resectable Non-small Cell Lung Cancer

Germany
Huashan Hospital

Recruiting

[68Ga]Ga-NOTA-RW102 PET Imaging in the Diagnosis of PD-L1-expressing Lung Cancer

Non-small Cell Lung Cancer

China
Regeneron Pharmaceuticals

Not yet recruiting

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-small Cell Lung Cancer That Can be Treated With Surgery.

Resectable Non-small Cell Lung Cancer
Sun Yat-sen University

Recruiting

The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC

Non-small Cell Lung Cancer

China
3D Medicines (Sichuan) Co., Ltd.

Recruiting

Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC

Non-small Cell Lung Cancer

China
BeiGene

Recruiting

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Advanced Breast Cancer | Metastatic Breast Cancer | Advanced Solid Tumor | Non-small Cell Lung Cancer | Hormone Receptor Positive Malignant Neoplasm of Breast | Hormone Receptor Positive Breast Carcinoma | HER2-negative Breast Cancer | Hormone Receptor Positive HER-2 Negative Breast Cancer | Hormone-receptor-positive...

Australia, United States
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer

Stage II-IIIB(N2) Non-small Cell Lung Cancer

China
Kunming Medical University

Recruiting

A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

China
BeiGene

Recruiting

Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

China, Georgia, Moldova, Republic of
Icahn School of Medicine at Mount Sinai

Recruiting

Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC

Non-Small Cell Lung Cancer

United States
Peking University Cancer Hospital & Institute
Geneplus-Beijing Co. Ltd.

Recruiting

Significance of MRD Monitoring in Patients With Potentially Resectable Stage III Non-small Cell Lung Cancer (MRDinS3LC)

NSCLC

China
University Hospital, Ghent
Hasselt University; Jessa Hospital; AZ Sint-Jan AV; AZ Delta; Ziekenhuis Oost-Limburg

Recruiting

Physical Activity Coaching After Surgery for Patients With Resectable Non-small Cell Lung Cancer (LucaMove)

Non Small Cell Lung Cancer | Non-small Cell Carcinoma

Belgium
Chinese University of Hong Kong

Recruiting

Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer

Lung Cancer

Hong Kong
Incyte Corporation
Mirati Therapeutics Inc.

Recruiting

A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation

Advanced Solid Tumors

United States, Canada, Italy, Spain, United Kingdom
Daping Hospital and the Research Institute of Surgery...

Not yet recruiting

Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients.

Non Small Cell Lung Cancer | EGFR Gene Mutation
Emory University
National Cancer Institute (NCI)

Not yet recruiting

Proton Beam Radiation Therapy After Treatment for Resected N2 Non-Small Cell Lung Cancer

Resectable Lung Non-Small Cell Carcinoma

United States
Hunan Province Tumor Hospital

Recruiting

A Real-World Study of Atezolizumab in Combination With Platinum-Based Doublet Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-IIIB NSCLC

NSCLC

China
Shanghai Zhongshan Hospital
Ningbo No. 1 Hospital; Shanghai Minhang Central Hospital; Xuhui Central Hospital... and other collaborators

Not yet recruiting

Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC

Non-Small Cell Lung Cancer
Hunan Cancer Hospital

Recruiting

A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC

Carcinoma, Non-Small-Cell Lung

China
AstraZeneca

Recruiting

Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE) (MDT-BRIDGE)

Non-small Cell Lung Cancer

Spain, Italy, France, Canada, Portugal, United States, Czechia, Germany, Sweden, Austria, Hungary
DualityBio Inc.

Recruiting

A Study of DB-1311 in Advanced/Metastatic Solid Tumors

Advanced Solid Tumors

United States, Australia
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial

Stage III Non-small Cell Lung Cancer
Second Affiliated Hospital, School of Medicine,...

Recruiting

Serplulimab Combined With Chemotherapy in Patients With Resectable Non-small-cell Lung Cancer

NSCLC | Neoadjuvant Therapy

China

3

Subscribe